Jeroen van Beek
Geen lopende functies
Vermogen: 196 062 $ op 31-03-2024
Profiel
Jeroen van Beek worked as a Marketing Director at Pfizer Inc. from 1999 to 2007.
He then worked as VP-Global Commercial Operations & Development at Alexion Pharmaceuticals, Inc. from 2007 to 2017.
In 2018, he briefly worked as Chief Commercial Officer & Senior Vice President at Tricida, Inc. From 2019 to 2022, he worked as Chief Commercial Officer & Executive VP at AlloVir, Inc. Dr. van Beek received his undergraduate degree from the University of Virginia, his doctorate from Cornell University, and his MBA from the University of Virginia Darden School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ALLOVIR INC
0.23% | 10-03-2023 | 259 685 ( 0.23% ) | 196 062 $ | 31-03-2024 |
Eerdere bekende functies van Jeroen van Beek
| Bedrijven | Functie | Einde |
|---|---|---|
| ALLOVIR, INC. | Corporate Officer/Principal | 23-11-2022 |
| TRICIDA, INC. | Corporate Officer/Principal | 31-08-2018 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2017 |
| PFIZER, INC. | Sales & Marketing | 01-01-2007 |
Opleiding van Jeroen van Beek
| University of Virginia | Undergraduate Degree |
| Cornell University | Doctorate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| TRICIDA, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
